JAMA Network
About The Study: For Food and Drug Administration (FDA)-approved cell and gene therapies, commercial health plans commonly imposed coverage requirements beyond FDA-approved product labeling. These restrictions were often aligned with pivotal trial criteria, suggesting that plan coverage aligns with stronger supporting evidence.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
